Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15670551 | 1.00 | KCNN4 (0.37) | KCNN4HCAR2CA2MAPTMEN1 | |
| SCHEMBL4398746 | 0.79 | CA2 (0.41) | KCNN4CA2MAPTMEN1KMT2A | |
| SCHEMBL15670207 | 0.79 | KCNN4 (0.44) | KCNN4HCAR2CA2MAPTMEN1 | |
| SCHEMBL15670884 | 0.78 | GRM5 (0.37) | KCNN4HCAR2CA2MAPTMEN1 | |
| SCHEMBL15670885 | 0.78 | GRM5 (0.37) | KCNN4HCAR2CA2MAPTMEN1 | |
| SCHEMBL2366727 | 0.70 | CA2 (0.42) | CA2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1443388 | 0.70 | CA2 (0.42) | CA2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL1443385 | 0.70 | CA2 (0.42) | CA2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL30738485 | 0.69 | CA2 (0.41) | CA2MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL30738477 | 0.69 | CA2 (0.41) | CA2MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912034-B1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-9611232-B2 | Oxazolidinone and imidazolidinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150246894-A1 | NOVEL OXAZOLIDINONE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| EP-2912034-A1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | F. Hoffmann-La Roche AG (CH) | 2015-09-02 | — | — | EP | disclosed |
| WO-2014067861-A1 | 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246894-A1 | NOVEL OXAZOLIDINONE COMPOUNDS | OXA1L, CDK11B, CDK11A | KCNN4 1834/4885HCAR2 2935/4885CA2 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.